Background: Production of transgenic pigs for multiple transgenes is part of a potential strategy to prevent immunological events involved in xenograft rejection. Use of a genetically engineerable rodent as a donor in primates could allow testing in vivo of the effects of differ-
first step in the development of a donor containing multiple transgenes, transgenic rats for human decay-accelerating factor (DAF) were used as heart donors to test their resistence against complement (C)-mediated rejection by non-human primates.
Materials and Methods: Transgenic rats were generated by using a construct containing the human DAF cDNA under the transcriptional control of the endothelial cell (EC)-specific human ICAM-2 promoter. DAF expression was evaluated by immnunohistology and by FACS analysis of purified ECs. Resistance of transgenic hearts against C-mediated damage was evaluated by ex vivo perfusion with human serum and by transplantation into cynomolgus monkeys. Results: Immunohistological analysis of DAF expression in several organs from two transgenic lines showed uniform expression on the endothelium of all blood vessels. ECs purified from transgenic hearts showed 50% DAF expression compared to human ECs and >70% reduction of C-dependent cell lysis compared to control rat ECs. Hemizygous transgenic hearts perfused with human serum showed normal function for >60 min vs. 11.2 ± 1.7 min in controls.
Introduction
The use of porcine organs for clinical transplantation is an approach to overcoming the shortage of human organs. The first obstacle to xenotransplantation is the recipient's innate immune response which results in xenograft hyperacute rejection (HAR) (for review see refs. 1). Rejection of transplants performed between discordant species, such as pig to primates, involves the binding of preformed xenogeneic natural antibodies (XNA) directed to Galal1-3Gal epitopes on the endothelial cell (EC) surface (2, 3) . Interaction between XNA and their targets promotes complement (C) activation, leading to graft endothelium injury and activation (4) (5) (6) (7) . Prevention of xenograft HAR has been successfuly achieved by either inhibition of XNA binding through depletion of XNA or reduction of GalaI -3Gal expression on ECs (8, 9) , or by blockade of complement activation (10) . Transgenic pigs expressing human complement regulatory proteins (CRPs), including decay-accelerating factor (DAF) and/or CD59, have been produced to avoid complement-mediated graft damage (1 1-13). Dramatic improvement of xenograft survival has been obtained using these transgenic transplants in the pig-to-primate model of xenotransplantation (14) (15) (16) . These studies demonstrated that human DAF and/or CD59 expression on graft ECs, in association with antibody depletion and/or immunosuppressive regimen, efficiently overcome HAR. However, optimal transgene expression levels as well as its optimal tissue distribution remained to be determined.
Since xenograft HAR can be circumvented by the use of transgenic animals for CRPs, humoral and cell-mediated processes involved in delayed xenograft rejection or AVR may be further controlled by the production of transgenic animals expressing other transgenes acting on these processes in addition to CRPs. To this end, prior to the generation of transgenic pigs, production of transgenic small laboratory animals is needed. These animals would not only serve as tools for analysis of DNA construction for transgenesis but more impor-tantly would help us investigate in vivo the biological relevance of transgene expression on xenograft rejection. In addition, models bearing close resemblance to the pig-to-primate one may be particularly useful. In this regard, although transgenic mice have been used to define the expression of DNA construction (17, 18) and their organs perfused ex vivo, their reduced size make it nearly impossible to graft their organs in primates.
We previously established an in vivo experimental model for xenotransplantation using the rat as organ donor and an Old World primate (cynomolgus) as recipient. In this ratto-primate combination, HAR occurred 5 min after vascular anastomosis, with features mimicking HAR (19) and EC injury (7) observed in the pig-to-primate model. In addition, we demonstrated that, in vitro, human DAF and CD59 efficiently protect transfected xenogeneic rat ECs against cell lysis mediated by nonhuman primate sera (20) . In the present study, we investigated the ability of human DAF expressed by the endothelium to delay HAR by producing transgenic rats for the human DAF. Endothelium-specific transgene expression was analyzed by immunohistochemistry on tissue sections and quantitated in vitro by isolation of cardiac ECs followed by flow cytometry. Ex vivo perfusion of transgenic hearts with human serum demonstrated the ability of human DAF expression to prevent XNA and Cmediated organ damage. Correlation between the DAF expression level on graft ECs and graft survival time was documented following cardiac heterotopic transplantation using hemizygous and homozygous transgenic rats as donors and unmodified cynomolgus as recipients. Histopathological features of acute vascular rejection (AVR) of DAF-expressing cardiac xenograft were characterized by polymorphonuclear leukocytes (PMN) infiltration, intersticial edema, and focal myocardium necrosis.
Materials and Methods

Generation of Transgenic Rats
The plasmid expression vector phICAM2DAF (Fig. IA) contains a 1.9 kb EcoRI fragment of the human CD55 cDNA, 334 pb of the promoter region of the human intercellular adhesion molecule 2 (ICAM2) gene (nucleotides -292 to +44), a universal intron, and the SV40 polyA, as previously described (21 Analysis of complement activation was investigated following incubation of rat ECs with human serum (dilution 1:10) in DMEM medium for 30 min at 370C. Immunostaining was performed using FITC-labeled anti-human factor B, C3, C4 MAb (Atlantic Antibodies, Stillwater, MN) and an anti-human C5b-9 polyclonal serum as first antibodies revealed using FITC-labeled goat anti-rabbit IgG or IgM (Jackson Lab). Fluorescence was measured on 10,000 cells per sample using a FACScalibur (Becton Dickinson). Data are depicted in histograms plotting mean fluorescence intensity (MFI) on a log scale (xaxis) versus cell number (y-axis). 20 min, blocked with rat serum at 10% in PBS!/1% BSA, and incubated at room temperature for 60 min with MAb at 10 Ag/ml. Tissue sections were then incubated with biotin-conjugated horse anti-mouse IgG absorbed with rat serum proteins (Vector, Burlingame, CA) followed by horseradish peroxidase streptavidin (Vector) and developed with very intense purple (VIP kit, Vector). Slides were then counter stained with hematoxilin and mounted with glycerol. The following antibodies were used in this study: anti-rabbit vWf, anti-human DAF (1H4), and purified human anti-Gala1-3Gal antibody. Negative controls were performed using an isotype-matched irrelevant MAb (3G8). Semiquantitative analysis of DAF expression on endothelium was obtained by visual evaluation of the intensity of specific staining, which was ranked from 0 to 4 (0, no staining; 1, low intensity; 2, medium intensity; 3, high intensity; 4, very high intensity). Cardiac xenografts were analyzed for complement and xenogeneic antibody binding by immunofluorescence. Cynomolgus Ig binding was revealed through FITC-labeled goat F(ab')2 anti-human IgM (Fc,u) 20 human type-A plasma) diluted with the solution from the large reservoir. Before serum perfusion, hearts were allowed to stabilize by perfusing them with the Krebs-HenseleitHaemaccel solution for 10 min. The hearts were monitored continuously for heart rate, apex amplitude, and flow by means of multichannel registration. Duration of heart function was defined as the time between the start of serum perfusion and complete cessation of heart beat. Decomplementation was performed by heating the serum for 1 hr at 560C. Hemizygous rats (n = 5) from the transgenic line 52.2 were tested and compared to wild-type (WT) rats (n = 5).
Cardiac Xenografts into Primates
Transgenic and WT Sprague-Dawley rats of 300-400 g body weight were used as donors and cynomolgus monkeys of 6-9 kg body weight were used as recipients. Heterotopic heart xenotransplantation was performed as previously described (19) . To compare graft survival of heart from hemizygous and homozygous transgenics, one of each organ was concomitantly grafted onto the same recipient in each femoral vessel. Xenograft survival was determined by visual examination and palpation of xenogeneic heart beating. Histological analysis of rejected xenografts was performed on paraffin-embedded sections (5 ,um) stained with hematoxilin-eosin.
Statistical Analysis All data (mean + SD) were analyzed using the Student's t-test, with p < 0.05 being the level of significance.
Results
Production of Transgenic Rats for Human DAF and Transgene Integration Analysis A total of 754 eggs was microinjected and subsequently reimplanted into 37 pseudopregnant foster mothers, 27 of whom gave birth to 145 rats. Transgene integration was first detected by PCR in six founder animals and then confirmed by Southern blot performed on genomic DNA. Figure 1 shows the presence of a human DAF sequence in a major restriction fragment of 3 Expression of human DAF was investigated in several organs from transgenic rats, including heart, kidney, liver, and lung, and on lymphoid organs (thymus, spleen). Cryosections of tissues were analyzed by immunohistology with an anti-human DAF MAb and compared to tissues from nontransgenic control rats. Consistent levels of DAF were detectable in tissues on progeny from lines 52.2 and 62.3. A low level of DAF was observed on line 52.4 while no expression was obtained for the lines 54.9, 58.3, and 70.8. For both transgenic lines (52.2 and 62.3), ECs expressing the transgene were detected in all analyzed tissues, including heart, kidney, lung, and liver. In these organs, DAF expression was restricted to both vascular (large and medium size vessels) and capillar endothelium as determined by comparison with the pattern of staining obtained with an antibody directed to vWf (data not shown). All tissues analyzed from rat 52.2 showed higher expression of human DAF than those in corresponding organs from line 62.3. The nontransgenic (WT) control rat showed no staining of the tissues analyzed. Specific stainings for human DAF obtained in heart and kidney from an hemizygous transgenic rat (line 52.2) are presented in Figure 2 . Confirmation of endothelium-specific DAF expression in transgenic Incubation of transgenic (hemizygous or homozygous) rat ECs with purified human antiGalal-3Gal antibodies showed binding of IgG and IgM XNA that was similar to that of ECs from WT nontransgenic rats (data not shown). Furthermore, ECs from either transgenic or control rats exhibited similar levels of Galal3Gal expression as measured by the binding of FITC-labeled Bandera simplicifolia lectin (data not shown). In vitro protection of DAF-expressing rat ECs against antibodies and complement-mediated cell cytotoxicity was measured by incubating rat ECs with serial dilutions of primate (cynomolgus) serum. As shown in Figure 5 , primate serum induced a dose-dependent lysis of nontransgenic ECs for serum dilutions ranging between 6% and 25%. Compared to WT rat ECs, ECs isolated from transgenic rats were protected according to the level of human DAF expressed on the cell surface. When ECs were incubated in the presence of 25% serum, protection against cell lysis was 74 ± 6% (p < 0.05) and 43 ± 4% (p < 0.05) for homozygous and hemizygous, respectively, compared to WT rat ECs (9.6 ± 0.3%, 20.9 ± 0.1%, and 36.8 ± 0.1% of cell lysis for homozygous, hemizygous, and WT, respectively). (Fig. 6 ). An overall reduction in C9 was also observed on rat ECs from homozygous transgenic rats whereas no effect of DAF expression was observed for C4 and factor B deposition.
Ex Vivo Perfusion
The functional ability of hearts from hemizygous DAF+l rats to prevent complement activation was investigated by ex vivo organ perfusion with 15% human serum. Cardiac function, assessed by cardiac frequence, was monitored over a 60-min perfusion time (Fig. 7) . Our data showed that for DAF-expressing transgenic rats (n = 5), heart rate was not affected by serum perfusion and remained stable throughout the experiment. Similarly, perfusion of WT rat hearts with heat-inactivated serum (n = 5) showed normal cardiac function (data not shown). In contrast, cardiac function failed rapidly after perfusion of WT rat hearts with XNA and complement-containing human serum and stoped at 11.2 ± 1.7 min (n = 5). Rat hearts were grafted on femoral vessels bilaterally for hemizygous and homozygous rats. Wild-type heart survival has been previously reported (19 classical but not the alternative pathway (Table 2) . Less C3 and C9 fragment deposition was observed on transgenic tissues than on that of rejected organs from WT rats.
Discussion
Genetically engineered animals offer a unique opportunity for using donor animal organs for clinical transplantation. Transgenic pigs, which express molecules that could control immunological events associated with xenograft rejection, could be the first suitable source of these transplants. Transgenic mice are useful models for the analysis of promoter tissue specificity and transgene expression levels (24, 25) . However, there are no mouse models available for the study of transplantation of vascularized organs into primates. Investigation of transgenic or knockout mouse models (although restricted to ex vivo perfusion experiments) can be informative for several aspects of transgene function, but they do not allow analysis of the broad range of humoral and cellular interactions between graft and recipient that operate in vivo (25, 26) . Therefore, we have postulated that production of transgenic rats, which can be used for xenotransplantation into primates (19) , could provide a useful in vivo model to test the benefits of genetic engineering interventions in xenotransplantation (22) . The first step in validating this model was to demonstrate that endotheliumdirected expression of human DAF in rat organs can delay xenograft HAR.
Transgene distribution in transgenic organs is a major concern for xenotransplantation. For membrane-bound proteins such as CRPs, transgenes should be expressed at least on ECs (the first target of XNA binding and complement activation), since few other cell types in the rat (and also the pig) express the Galal-3Gal epitope (7) . Our data show that endothelium-restricted transgene expression can be obtained in transgenic rats by using part of the human ICAM-2 gene promoter, and that tissue distribution of transgene expression in transgenic rats is almost identical to transgene expression in lines of transgenic mice (18 CD59 and DAF levels that were 67% and 45% of HUVEC levels, respectively, and had a 3-to 5-fold increased resistance against complement-mediated lysis in vitro (14) . Xenografts were shown to have variable survival periods compared with controls (range 6 hr to 5 days versus 0.5 hr to 1 hr, respectively), and survival could be prolonged by depletion of xenoreactive antibodies (16) . Importantly, in these transplantation trials, recipients also received extensive immunosuppressive and anti-coagulant treatment (14, 16, 29 (15) . However, these transgenic organs, even in immunosuppressed recipients, have been almost invariably rejected by AVR (30, 31) .
Nontransgenic rat hearts transplanted into primates have been rejected with a histological pattern of HAR showing endothelial cell damage, platelet microthrombi, and little PMN vascular accumulation (19) . In contrast, rat hearts transplanted into primates treated with cobra venom factor (19) or DAF transgenic hearts that have survived transplantation for at least 28 min have been rejected, with a histological pattern of AVR showing extensive thrombosis, leukocyte accumulation (mainly PMN) in the vessels and tissues, edema, and hemorrhage. Furthermore, increased levels of DAF in transplanted organs (from homozygous and hemizygous DAF transgenic rats) result in longer periods of graft survival that correlate with progressive PMN infiltration, hemorrhage, and focal myocardial necrosis. Similarly, AVR is the most common result of xenotransplantation between discordant species (guinea pig-to-rat or pig-to-primate) after XNA depletion, complement inactivation of recipients, or transplantation of CRP transgenic organs (4, 10, 12, (14) (15) (16) 32, 33) . Although AVR in these models share common pathological features (hemorrhage, edema, and presence of leukocytes), they also show differences in the type of infiltrating leukocytes. In transplant combinations involving rats as recipients, mononuclear cell infiltrates predominate (33, 34) , whereas combinations involving primates as recipients (especially when the primates do not receive immunosuppressive drugs) show leukocyte infiltrates with mononuclear cells and a high proportion of PMN (4, 15) .
Taken together, our results demonstrate that a moderate level of human DAF expression on rat endothelium prolongs xenograft survival beyond HAR and that the PMN infiltration, hemorrhage, and focal myocardial necrosis associated with AVR in pig-to-primate transplants are also present in rat-to-primate transplants. It is likely that higher levels of DAF expression are required to further improve xenograft survival, or that other factors in addition to complement (such as XNA binding to ECs and mechanisms such as coagulation and EC activation) must be controlled to prevent xenograft AVR.
In conclusion, xenotransplantation of transgenic organs expressing CRPs, from either pig or rat, prevents HAR but not the development of AVR, even when immunosuppressed primates are used as recipients (14) (15) (16) 30, 31) . Therefore, there is an urgent need to express new transgenes to protect xenografts and decrease the side effects of immunosuppression. These transgenes should probably be aimed at decreasing Galal3Gal expression or inhibiting coagulation and tissue infiltration by leukocytes. The development of transgenic rats represents a more rapid alternative than the production of transgenic pigs for testing the usefulness of new strategies and allows an easier analysis of mechanism of action. In this regard, the backcross of transgenic rats expressing DAF to prevent HAR, and the backcross of rats expressing Fas ligand in the endothelium (35) that could inhibit PMN adherence to endothelium (36) may facilitate analysis of the role of early leukocyte infiltration in AVR.
